Revance Therapeutics (RVNC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2019 | 06-2019 | 03-2019 | 12-2018 | 09-2018 | |
| Sales | 46 | 0 | 278 | 488 | 2,362 |
| Gross Profit | 46 | N/A | 278 | 488 | 2,362 |
| Operating Expenses | 42,586 | 39,122 | 36,905 | 38,900 | 36,003 |
| Operating Income | -42,540 | -39,122 | -36,627 | -38,412 | -33,641 |
| Other Income | 1,131 | 1,732 | 1,323 | 795 | 807 |
| Pre-tax Income | -41,409 | -37,390 | -35,304 | -37,617 | -32,834 |
| Net Income Continuous | -41,409 | -37,390 | -35,304 | -40,617 | -32,834 |
| Net Income | $-41,409 | $-37,390 | $-35,304 | $-40,617 | $-32,834 |
| EPS Basic Total Ops | -0.96 | -0.86 | -0.85 | -1.12 | -0.91 |
| EPS Basic Continuous Ops | -0.96 | -0.86 | -0.85 | -1.12 | -0.91 |
| EPS Diluted Total Ops | -0.96 | -0.86 | -0.85 | -1.12 | -0.91 |
| EPS Diluted Continuous Ops | -0.96 | -0.86 | -0.85 | -1.12 | -0.91 |
| EBITDA(a) | $-42,540 | $-39,164 | $-36,648 | $-38,136 | $-33,491 |